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Background 
The bisphosphonates are a group of products 
that are effective in the prevention and treatment 
of postmenopausal and glucocorticoid-induced 
osteoporosis and also Paget’s disease.  They 
increase bone density by binding to the surfaces of 
bones and slow down osteoclastic activity, 
thereby facilitating osteoblastic effectiveness.  
Alendronate (Fosamax) and risedronate (Actonel) 
are commonly prescribed bisphosphonate agents.  
The most common side effect of the 
bisphosphonates is gastrointestinal upset.  This is 
often dose-related.1-3 
Post-marketing surveillance data from several 
countries are revealing severe bone, joint, and 
muscle pain associated with these agents, 
specifically alendronate and risedronate.4-7   
 
Reported Events 
Since the marketing of Fosamax in the US 
beginning September 1995 up to November 2002, 
there have been 118 reports of severe bone, joint, 
and/or muscle pain in patients.  Ninety-six percent 
of these events occurred in women.  Of those 
cases for which sufficient information was 
provided, 74% occurred at a daily dose of 10 mg 
and 18% occurred with a once-weekly dosage of 
70 mg.  Pain onset ranged from the same day to 
52 months with an average of 14 days from 
therapy start.  In some patients, pain initiated in 
one site then migrated and became diffuse.  Pain 
was severe enough to require bedrest, walkers, or 
crutches and resulted in inability to perform usual 
activities for some patients.  Opioids, ketorolac 
(Toradol), or other agents were used to treat the 
pain.  In 66% of the patients, Fosamax was 
discontinued; some experienced immediate relief 
but most had gradual improvement.  Eleven 
percent of the patients for whom therapy was 
discontinued redeveloped pain after therapy 
restart.4  
Post-marketing surveillance data for Actonel 
from its marketing in September 1998 through 
June 2003 have revealed six severe cases of bone, 
joint, or muscle pain.  Specific demographic, 
epidemiologic, or dosage data have not been 
published at this time.4 
The Australian Adverse Drug Reactions 
Advisory Committee has received 61 reports of 
musculoskeletal adverse events since the 1996 
marketing of Fosamax there.  Of these 61 cases, 
35 reported muscle pain, 29 identified joint pain, 
six were associated with bone pain, and ten cases 
had mixed muscle and joint pain.  Onset of pain 
ranged from the start day to over one year of 
therapy.  Pain recurred in 13% of those re-
challenged with the drug.5 
Data from the Canadian Adverse Drug 
Reaction Monitoring Program for the time period 
of December 1995 to January 1998 identified two 
cases of alendronate-associated musculoskeletal 
pain from a total of 138 reports.  One case 
involved exacerbation of rheumatoid arthritis with 
accompanying gastrointestinal complaints in a 64 
year old woman after receiving alendronate 10 mg 
daily for four weeks.6 
In a study of alendronate-associated 
esophageal reaction incidence by Mackay et al, 
the researchers used a calculated incidence density 
for reporting events.  In their study period 
nausea/vomiting incidence was 8.3, dyspepsia 
incidence was 11.3, abdominal pain incidence was 
7.5, back pain incidence was 5.3, and joint pain 
incidence was 4.1.7  
 
Commentary 
These data suggest an association of 
bisphosphonate-related musculoskeletal pain.  
However, there is no specific baseline data on the 
incidence of existing musculoskeletal conditions 
in these patients.  This makes the clinical 
significance of these observations difficult to 
determine.  Furthermore, underreporting of these 
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musculoskeletal adverse events may occur due to 
confusion of drug-related vs disease-related 
conditions such as pre-existing osteoporosis or 
osteoarthritis.  It is interesting to note that in the 
therapy discontinuation cases mentioned above, 
pain reoccurred with bisphosphonate rechallenge 
in only 11 to 13% of recorded cases.4,5   
Newly reported cases of musculoskeletal pain 
following initial or prolonged treatment with 
bisphosphonate agents should be checked.  A 
bisphosphonate discontinuation trial may be 
initiated to potentially determine an association 
when other causes of pain have been ruled-out.  
Other non-bisphosphonate agents that may be 
used for osteoporosis include estrogen 
replacement (based on the individual woman’s 
history and risk factors and used for the shortest 
period at the lowest possible dose), raloxifene 
(Evista), calcitonin (Miacalcin), and synthetic 
parathyroid hormone (Forteo).  Adequate calcium 
and vitamin D are essential supplements but not 
adequate alone for treatment.1,2 
Encourage reporting of suspected adverse drug 
events.  To report adverse events in the US, call 
the FDA MEDWATCH program at 1-800-FDA-
1088. The MEDWATCH program is also 
available on-line at www.fda.gov/medwatch.  In 
Canada, call the Canadian Adverse Drug Reaction 
Monitoring Program at 1-866-234-2345.  The 
Canadian adverse reaction reporting form can be 
found at: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-
dpt/adverse_e.pdf.  It should be completed and 
faxed to 1-866-678-6789.   
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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